Ajanta Pharma reported a consolidated net profit of ₹334.22 crore for the quarter ended June 30, 2026, marking a 30.9% year-on-year increase from ₹255.34 crore in Q1FY26. The growth was primarily driven by a 57% surge in US Generic revenues to ₹487 crore and robust performance in its India branded generics segment, which grew 24% to ₹509 crore. Total consolidated revenue from operations rose 24.8% to ₹1,625.96 crore, reflecting strong operational momentum across key therapeutic areas including cardiology, ophthalmology, and dermatology. Shareholders will receive an interim dividend of ₹32 per share, with payments scheduled on or after August 18, 2026.

The Board of Directors approved the unaudited financial results at its meeting held on July 30, 2026, in compliance with Regulations 33, 42, and 43 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Alongside the results, the Board declared a first interim dividend of ₹400 crore for financial year 2027, translating to ₹32 per share on the face value of ₹2 per share. The record date for dividend payment is fixed at August 5, 2026. Statutory auditors M/s B S R & Co. LLP issued limited review reports on both consolidated and standalone financial results.

Financial Performance Overview

Consolidated earnings before tax stood at ₹446.80 crore, compared to ₹331.13 crore in Q1FY26. Adjusted EBITDA (excluding forex loss) increased 21% to ₹454 crore against ₹377 crore in the prior-year period, maintaining a margin of 28%. Standalone net profit after tax rose 23.7% to ₹315.47 crore from ₹254.97 crore in Q1FY26. Standalone revenue from operations increased 23.2% to ₹1,488.67 crore.

Earnings per share on a basic consolidated basis reached ₹26.72, up from ₹20.43 in Q1FY26. Return on Capital Employed (ROCE) stood at 37%, while Return on Net Worth (RONW) was 28%. Research and development expenses rose to ₹66 crore, representing 4% of revenue.

Segment-Wise Growth Drivers

The company’s diversified portfolio delivered varied growth rates across geographies. The Africa Institution business saw an 83% jump to ₹70 crore from ₹38 crore. In contrast, Asia branded generics declined 16% to ₹255 crore from ₹304 crore, likely due to market-specific dynamics. Overall, branded generics sub-total grew 13% to ₹1,059 crore.

In India, Ajanta Pharma’s branded generic performance exceeded the Indian Pharmaceutical Market (IPM) growth by 36% as per IQVIA MAT June 2026 data. New launches outperformed IPM by 76%, while volumes exceeded IPM by 40%. Key therapy segments such as Ophthalmology (15% vs 10% IPM), Dermatology (14% vs 8% IPM), and Pain Management (15% vs 10% IPM) contributed significantly to this outperformance.

Regulatory and Operational Updates

Ajanta Pharma continues to strengthen its US pipeline, with 51 ANDAs commercialized as of Q1FY27. The company received three new approvals and launched two products during the quarter. Currently, 17 applications await approval with the US FDA, and five hold tentative approval status.

Regarding regulatory matters, the company noted that Income Tax Authorities carried out search operations in August 2025. The company filed returns for the block period from April 1, 2019, to November 17, 2025, on April 6, 2026. Management stated that the consequent impact on consolidated financial results for the quarter ended June 30, 2026, is currently not ascertainable pending further communication from authorities.

What the Numbers Show

The divergence between revenue growth (24.8%) and profit growth (30.9%) indicates an expansion in operating margins during the quarter. With adjusted EBITDA margins holding steady at 28% despite higher forex volatility (foreign exchange gain of ₹50.47 crore offset by loss of ₹30.59 crore), the company demonstrates resilient cost management. The substantial interim dividend payout of ₹400 crore underscores management’s confidence in cash flow generation capabilities for the remainder of FY27.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE031B01049/1be40f2ef982457c.pdf

Ajanta Pharma has fixed August 5, 2026, as the record date for determining shareholders eligible for its first interim dividend of ₹32 per share. The declaration follows the company’s robust Q1FY27 results, where consolidated net profit surged 31% year-on-year to ₹334 crore, while revenue from operations expanded 25% to ₹1,626 crore. This dividend payout, totaling approximately ₹400 crore, underscores management’s confidence in cash generation despite ongoing tax scrutiny and operational headwinds in certain emerging markets.

The Board of Directors approved the dividend on July 30, 2026, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors M/s B S R & Co. LLP issued an unmodified conclusion on the quarterly results. Shareholders holding equity shares on the record date will receive the dividend, with payments scheduled for August 18, 2026, or later. The company operates under an open book closure system, meaning there is no specific book closure period; eligibility is determined solely by the shareholding pattern as of the close of business on the record date.

Q1FY27 Financial Performance

Ajanta Pharma’s top-line growth was broad-based, driven primarily by exceptional performances in its US Generic and Africa Institutional segments. While India’s branded generic business grew 24% to ₹509 crore, Asia saw a 16% decline to ₹255 crore. However, these were offset by a 57% surge in US Generic revenues to ₹487 crore and an 83% jump in Africa Institutional business to ₹70 crore.

Segmental Insights and Operational Efficiency

In India, Ajanta Pharma outperformed the Indian Pharmaceutical Market (IPM) growth rate of 11% with a 15% overall growth. New launches contributed significantly, growing 76% against IPM, while volumes grew 40%. Key therapeutic areas such as Ophthalmology, Dermatology, and Pain Management all exceeded IPM growth rates. The company maintains a strong pipeline with 51 commercialized ANDAs in the US, 17 awaiting FDA approval, and 5 holding tentative approvals.

R&D expenses increased to ₹66 crore (4% of revenue) from ₹56 crore in Q1FY26, reflecting continued investment in formulation capabilities across its seven manufacturing facilities. Despite revenue growth, adjusted EBITDA margin contracted slightly from 29% to 28%, indicating that operating costs rose marginally faster than sales, although absolute earnings power improved significantly.

What the Numbers Show

The divergence between the 25% revenue growth and 31% profit growth highlights improved operational leverage and favorable mix shifts towards higher-margin US generics. The 57% surge in US revenues suggests successful market penetration or volume gains in key molecules. Furthermore, the substantial ₹400 crore dividend payout, representing over 100% of the quarterly net profit, signals strong underlying cash generation capabilities, even as the company navigates tax search operations initiated in August 2025. The impact of these searches remains unquantifiable for Q1FY27, posing a potential future risk to retained earnings.